title: Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia.
abstract: Effects of quetiapine on cognition were assessed in a group of first-episode antipsychotic-naïve patients with schizophrenia (N=24). A comprehensive battery of neuropsychological tests was administered at baseline and after 6 months of treatment with quetiapine. In order to examine retest effects, a matched healthy control group (N=24) was also tested at baseline and after 6 months. Only few differential changes were observed between patients and healthy controls. Of 8 cognitive domains examined, only significant changes in executive function suggested possible ameliorating effects of quetiapine. Patients also improved on speed of processing; however, this was parallel to the retest effects found in healthy controls. When covaried for differences at baseline, patients showed smaller improvements in speed of processing than the retest effects found in controls, as well as a lack of retest effects on sustained attention and working memory that were found in healthy controls. The main result of the study is that there was very little evidence of efficacy of quetiapine on cognition. The study also indicated a lack of normal retest effects in patients compared to controls.
authors.affiliation: Copenhagen University Hospital, Psychiatric Center Glostrup, Denmark. rune@cnsr.dk
authors.forename: Rune
authors.initials: R
authors.lastname: Andersen
authors.forename: Birgitte
authors.initials: B
authors.lastname: Fagerlund
authors.forename: Hans
authors.initials: H
authors.lastname: Rasmussen
authors.forename: Bjorn H
authors.initials: BH
authors.lastname: Ebdrup
authors.forename: Bodil
authors.initials: B
authors.lastname: Aggernaes
authors.forename: Anders
authors.initials: A
authors.lastname: Gade
authors.forename: Bob
authors.initials: B
authors.lastname: Oranje
authors.forename: Birte
authors.initials: B
authors.lastname: Glenthoj
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate; D012189:Retrospective Studies; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate